Cocrystal Pharma
COCP
22 hedge funds and large institutions have $1.73M invested in Cocrystal Pharma in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.09% more ownership
Funds ownership: 0.74% → 0.83% (+0.09%)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
70% less capital invested
Capital invested by funds: $5.71M → $1.73M (-$3.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$590K |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$538K |
| 3 |
Renaissance Technologies
New York
|
+$98.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.5K |
| 5 |
VF
Virtu Financial
New York
|
+$23.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$594K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$225K |
| 3 |
Millennium Management
New York
|
-$26K |
| 4 |
Jane Street
New York
|
-$22K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | +$80 | +8 | New |
|
|
SIC
27
Samalin Investment Counsel
Chappaqua,
New York
| – | +$829 | +83 | New |
|
COCP Hedge Fund Activity: Q4 2019 in Review
22 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q4 2019, worth a combined $1.73M — down 70% from $5.71M a quarter earlier.
Fund positioning in COCP was balanced in Q4 2019: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $590K. The largest seller was Royal Bank of Canada, cutting an estimated $594K.
- 22 institutional investors held Cocrystal Pharma (COCP) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1.73M of Cocrystal Pharma stock for Q4 2019, down 70% quarter-over-quarter.
- 5 funds opened new Cocrystal Pharma positions in Q4 2019 and 5 closed out, a net change of 0 holders.
- The largest Cocrystal Pharma buyer in Q4 2019 was Morgan Stanley, an estimated $590K added.
- The largest Cocrystal Pharma seller in Q4 2019 was Royal Bank of Canada, an estimated $594K sold.
Based on aggregated 13F filings for Q4 2019.